PUBLISHER: DelveInsight | PRODUCT CODE: 1105540
PUBLISHER: DelveInsight | PRODUCT CODE: 1105540
DelveInsight's, Type 1 Diabetes - Pipeline Insight, 2022," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Type 1 Diabetes Understanding
Type 1 Diabetes: Overview
Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.
The development of T1DM occurs in 3 stages. Stage 1 is asymptomatic and characterized by normal fasting glucose, normal glucose tolerance, and the presence of greater than or equal to 2 pancreatic autoantibodies. Stage 2 diagnostic criteria include the presence of greater than or equal to 2 pancreatic autoantibodies and dysglycemia: impaired fasting glucose (glucose of 100 to 125 mg/dl) or impaired glucose tolerance (2-hour PG of 140 to 199 mg/dL) or a hemoglobin A1c between 5.7% to 6.4%. Individuals remain asymptomatic. In stage 3, there is diabetes or hyperglycemia with clinical symptoms and two or more pancreatic autoantibodies.
"Type 1 Diabetes - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Type 1 Diabetes Emerging Drugs
Teplizumab: Prevention Bio
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.
Emricasan: Histogen
Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.
VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection
Further product details are provided in the report……..
Type 1 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 100+ key companies which are developing the therapies Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio
DelveInsight's report covers around 100+ products under different phases of clinical development like
Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Type 1 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Type 1 Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Type 1 Diabetes- DelveInsight's Analytical Perspective
Late Stage Products (Preregistration)
Teplizumab: Provention Bio
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TTP 399: Novo Nordisk
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SBP 101: Takeda Oncology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Eflornithine oral: Panbela Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Type 1 Diabetes Key Companies
Type 1 Diabetes Key Products
Type 1 Diabetes- Unmet Needs
Type 1 Diabetes- Market Drivers and Barriers
Type 1 Diabetes- Future Perspectives and Conclusion
Type 1 Diabetes Analyst Views
Type 1 Diabetes Key Companies